Celsion Announces Date From Phase I Immuno-Oncology Study In Ovarian Cancer Patients; Data Showed GEN-1 Was Tell Tolerated And That Intraperitoneal Administration Is Feasible With Broad Patient Acceptance
Benzinga_Newsdesk